Susrutha Puthanmadhom Narayanan1, Adil E Bharucha2. 1. Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street, Rochester, MN, 55905, USA. 2. Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street, Rochester, MN, 55905, USA. bharucha.adil@mayo.edu.
Abstract
PURPOSE OF REVIEW: Biofeedback therapy (BFT) is effective for managing pelvic floor disorders (i.e., defecatory disorders and fecal incontinence). However, even in controlled clinical trials, only approximately 60% of patients with defecatory disorders experienced long-term improvement. The review serves to update practitioners on recent advances and to identify practical obstacles to providing biofeedback therapy. RECENT FINDINGS: The efficacy and safety of biofeedback therapy have been evaluated in defecatory disorders, fecal incontinence, and levator ani syndrome. Recent studies looked at outcomes in specific patient sub-populations and predictors of a response to biofeedback therapy. Biofeedback therapy is effective for managing defecatory disorders, fecal incontinence, and levator ani syndrome. Patients who have a lower bowel satisfaction score and use digital maneuvers fare better. Biofeedback therapy is recommended for patients with fecal incontinence who do not respond to conservative management. A subset of patients with levator ani syndrome who have dyssynergic defecation are more likely to respond to biofeedback therapy.
PURPOSE OF REVIEW: Biofeedback therapy (BFT) is effective for managing pelvic floor disorders (i.e., defecatory disorders and fecal incontinence). However, even in controlled clinical trials, only approximately 60% of patients with defecatory disorders experienced long-term improvement. The review serves to update practitioners on recent advances and to identify practical obstacles to providing biofeedback therapy. RECENT FINDINGS: The efficacy and safety of biofeedback therapy have been evaluated in defecatory disorders, fecal incontinence, and levator ani syndrome. Recent studies looked at outcomes in specific patient sub-populations and predictors of a response to biofeedback therapy. Biofeedback therapy is effective for managing defecatory disorders, fecal incontinence, and levator ani syndrome. Patients who have a lower bowel satisfaction score and use digital maneuvers fare better. Biofeedback therapy is recommended for patients with fecal incontinence who do not respond to conservative management. A subset of patients with levator ani syndrome who have dyssynergic defecation are more likely to respond to biofeedback therapy.
Authors: Sushmitha Grama Srinivasan; Anjani Muthyala; Mayank Sharma; Kelly Feuerhak; Andrea Boon; Kent R Bailey; Adil E Bharucha Journal: Clin Gastroenterol Hepatol Date: 2021-12-08 Impact factor: 13.576
Authors: Paul T Heitmann; Paul F Vollebregt; Charles H Knowles; Peter J Lunniss; Phil G Dinning; S Mark Scott Journal: Nat Rev Gastroenterol Hepatol Date: 2021-08-09 Impact factor: 46.802
Authors: Brototo Deb; Mayank Sharma; Joel G Fletcher; Sushmitha Grama Srinivasan; Alexandra Chronopoulou; Jun Chen; Kent R Bailey; Kelly J Feuerhak; Adil E Bharucha Journal: Gastroenterology Date: 2021-12-22 Impact factor: 22.682
Authors: Mayank Sharma; Ann C Lowry; Satish S Rao; William E Whitehead; Lawrence A Szarka; Frank A Hamilton; Adil E Bharucha Journal: Neurogastroenterol Motil Date: 2021-01-18 Impact factor: 3.960